Last checked at 30 Aug 2012 11:14
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Notice of results and shareholder update
Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its Preliminary Results for the year ended 30 June 2012 on Monday 17 September 2012.
The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2012 on the 30 August 2012. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.
Balance Sheet as at 31 March 2012
£ '000 | |
Total Non-Current Assets | 15,085 |
Total Current Assets | 17,207 |
Total Current Liabilities | (19,027) |
Total Non-Current Liabilities | (4,316) |
Total Equity | 8,949 |
Consolidated Income Statement for the 6 months ended 31 March 2012
£'000 | |
Revenue | 27,595 |
Profit after tax for the period | 6,777 |
Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2011.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Nomura Code Securities | +44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw | |
FTI Consulting | +44 (0) 207 831 3113 |
Simon Conway/ Susan Stuart |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.